GLS and neoplasm: The conversion of Gln to ketoglutarate, a tricarboxylic acid cycle intermediate, via glutaminase and alanine aminotransferase, is critical for tumor development, and thus targeted therapy by selective inhibition of GLS is a novel strategy of considerable interest for the treatment of cancer.